AstraZeneca-Ionis Partnered Rare Disease Drug Data Shows Sustained Benefit; Drug Under FDA Review

• Ionis Pharmaceuticals Inc (NASDAQ: IONS) released topline results from the 66-week analysis of Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca Plc's (NASDAQ: AZN) eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) that leads to peripheral nerve damage and motor disability.

• At 66 weeks, patients treated with eplontersen demonstrated a statistically significant and clinically meaningful change from baseline versus an external placebo group on the co-primary endpoints of modified Neuropathy Impairment Score +7 (mNIS+7), a measure of neuropathic disease progression and Quality of life.

• The study also met its third co-primary endpoint, demonstrating a statistically significant reduction in serum TTR concentration versus an external placebo group.

• TTR reductions were consistent with those reported at week 35.

• Eplontersen exhibited a safety and tolerability profile consistent with that observed at 35 weeks.

• Data from the 35 and 66-week analyses will be presented as an Emerging Science presentation at the April American Academy of Neurology Annual Meeting.

• Earlier this month, FDA accepted a marketing application for eplontersen with a PDUFA action date of Dec. 22, 2023. Eplontersen was granted Orphan Drug Designation in the U.S.

• Eplontersen is currently being evaluated in the Phase 3 CARDIO-TTRansform study for transthyretin amyloid cardiomyopathy.

• Price Action: IONS shares are up 0.32% at $34.06 on the last check Monday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article AstraZeneca-Ionis Partnered Rare Disease Drug Data Shows Sustained Benefit; Drug Under FDA Review originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.